

PRODUCT FACTSHEET
REVERSE CONVERTIBLE BOND 10 % IMPFSTOFF PLUS AKTIENANLEIHE



ISIN : AT0000A2QM90 / WKN: RC03H7
INVESTMENT Product without Capital Protection
Barrier Reverse Convertible Plus Bonds

The product related information contained herein is exclusively for information purposes only, intended for current investors or in case these products are displayed further to an individual search. The information does not constitute a recommendation or an offer to buy or an invitation to make a respective offer in relation to any of the products described herein.

CHG. 1D -0.720 (-0.66%)	BID 108.35%	ASK 109.85%	LAST UPDATE Jun 11, 2021 17:59:44.835
BARRIER EUR 60.00	STRIKE EUR 100.00	MAX. YIELD P.A. 4.96%	INTEREST RATE P.A. 10.00%

KEY DATA

Underlying	10 % Impfstoff Plus Aktienanleihe
Underlying price (delayed)	-
Underlying date/time	-
Barrier	EUR 60.00
Barrier reached	no
Observation barrier	on the final valuation date
Distance to barrier	38.49%
Strike	EUR 100.00
Distance to strike	-2.51%
Interest rate total term	-
Fixed interest rate annually	10.00%
Accrued interest	Dirty (included in the price)
Max. yield remaining term (%)	9.24%
Max. yield p.a.	4.96%
Maturity date	May 12, 2023
Final valuation date	May 09, 2023
Issue date	May 12, 2021
Tradeable unit/nominal value	EUR 1,000
Expected market trend	sideways, bullish
Listing	Vienna, Frankfurt, Stuttgart
Product currency	EUR
Underlying currency	EUR
Settlement method	Cash settlement / Physical delivery
No. of shares	-
Taxation	Capital Gains Tax / Foreign Capital Gains Tax

DESCRIPTION

The **10% Vaccine Plus Reverse Convertible Bond** is redeemed at 100% of the nominal value at the maturity date (May 2023), provided that the closing price of each of the three underlying shares (Johnson & Johnson, Moderna and Pfizer) quotes above the barrier of 60% of the respective strike at the end of the term (observation only at the final valuation date). The interest amount of 10% is paid out annually, regardless of the performance of the underlying shares.

In case at least one of the underlying shares quotes below its barrier (60%) at the final valuation date, the predefined amount of the worst performing share will be delivered.

PRICE DEVELOPMENT SINCE ISSUE DATE



UNDERLYING 10 % IMPFSTOFF PLUS AKTIENANLEIHE - BASKET MEMBERS

NAME ISIN	CUR	START VALUE	BARR.	PRICE	DIST. % TO BARR.	NUM. SHARES	CHG. % PREV. DAY	CHG. % START	LAST UPDATE
Moderna Inc US60770K1079	USD	158.99	95.39	218.78 (indicative)	56.40%	6.29	0.81%	37.61%	Jun 11, 2021 10:00 PM
Pfizer Inc US7170811035	USD	39.35	23.61	40.15 (indicative)	41.19%	25.41	-1.30%	2.02%	Jun 11, 2021 10:00 PM
Johnson & Johnson US4781601046	USD	168.88	101.33	164.95 (indicative)	38.57%	5.92	-1.26%	-2.32%	Jun 11, 2021 10:00 PM

CONTACT/INFORMATION

E:	produkte@rcb.at
T:	+43-1-51520-484
RCB website	www.rcb.at

This advertisement serves as non-binding information. The author assumes no responsibility for the accuracy, timeliness and completeness of this advertisement. The provided information is not an offer and is neither a recommendation nor a financial analysis. It does not replace investor-oriented and investment-oriented advice for the purchase and sale of the financial instrument. The base prospectus (including possible amendments) and the respective Key Information Document (KID) of the financial instrument are available on the website of Raiffeisen Centrobank AG ("RCB") at www.rcb.at/en/securitiesprospectus. The approval of the Base Prospectus by the FMA should not be understood as an endorsement of the financial instruments described herein by the FMA. You are about to purchase a product that is not simple and may be difficult to understand. We recommend that you read the prospectus before making an investment decision. The investor bears the credit risk of RCB when purchasing the financial instrument. The certificate is subject to specific rules that may already be disadvantageous in case of a probable default of RCB (e.g. suspension of interest payments) - see www.rcb.at/en/basag. The price performance shown here is only an information about the historical price performance. Information on past performance is not a reliable indicator of future performance. The investment may lead to tax obligations that vary depending on the client's personal circumstances and future changes. Any limited tax liability in Austria concerning non-resident taxpayers does not imply tax exemption in the state of residence. Please note that due to legal requirements, the times stated here are based on the coordinated world time (UTC). The Central European Time (CET), which applies in Austria, Germany and other Central European countries, is calculated by adding one hour, the summer European Central Summer Time (CEST) by adding two hours. RCB is registered in the business register FN 11507 f.